What the SURMOUNT trials mean for your tirzepatide decision

What decision is the SURMOUNT evidence actually helping you make?

Most people reading about the SURMOUNT trials are trying to answer a practical question: is tirzepatide likely to work for me, and how does it compare to other options? That is a reasonable thing to want to know before starting treatment. The programme was designed to help clinicians answer exactly that, by testing tirzepatide in controlled conditions, at each dose, across different types of patient.

One misconception worth setting aside gently: SURMOUNT does not tell you what you will lose. Trial averages describe what happened across a population; individual results vary based on starting weight, diet, activity, adherence and biology. What the data does tell you is the likely range of outcomes, and how tirzepatide performs relative to doing nothing, and relative to semaglutide. That contextual picture is what makes the SURMOUNT findings genuinely useful, rather than just a headline figure.

Our tirzepatide overview sets out how the medicine works as a dual GIP and GLP-1 receptor agonist, the mechanism that distinguishes it from single-pathway GLP-1 treatments and that the SURMOUNT trials were in part designed to test at scale.

What SURMOUNT-1 and SURMOUNT-3 tell you about dose and magnitude

SURMOUNT-1 is the anchor trial. It ran for 72 weeks, enrolled 2,539 adults with a BMI of 30 or above (or 27 with at least one weight-related condition), and excluded people with type 2 diabetes, so its results apply specifically to the weight-management population. Average weight reduction reached around 15% at the 5mg dose, rising to approximately 20–21% at 15mg, findings cited directly by NICE in their appraisal of tirzepatide (TA1026).

SURMOUNT-3 added an important nuance: participants who completed an intensive lifestyle programme before starting tirzepatide lost even more on average. This points to something clinicians find clinically significant, tirzepatide appears to work alongside behavioural effort rather than instead of it. If you are prepared to make real changes to diet and activity, the evidence suggests the combination produces better outcomes than either alone.

Treatment in all SURMOUNT trials started at 2.5mg, a dose chosen to allow the body to adjust rather than as a meaningful therapeutic target. Titration proceeded in steps decided by the trial protocol and, in real-world practice, by the prescriber. Dose progression is always a clinical decision.

What SURMOUNT-4 and SURMOUNT-5 answer about longer-term use and comparisons

SURMOUNT-4 addressed a question that SURMOUNT-1 left open: what happens if you stop? Participants who had already lost weight on tirzepatide were randomised to continue or switch to placebo. Those who stopped regained a substantial portion of the weight they had lost, which aligns with what is understood about obesity as a chronic condition. The implication for clinical practice is that tirzepatide is typically considered a long-term rather than short-term treatment.

SURMOUNT-5 took a different approach entirely. Published in the New England Journal of Medicine in 2025, it compared tirzepatide directly against semaglutide 2.4mg in 751 adults with obesity and no diabetes, over 72 weeks. Tirzepatide produced a greater average weight reduction. You can read the full breakdown of weight-loss percentages across the SURMOUNT trials for the specific figures, all cited to their source.

For the question of private access and what treatment involves financially, the context around Mounjaro's UK pricing is worth understanding before you start, costs changed in September 2025 and have been widely reported since.

How to use this evidence when speaking to a prescriber

The SURMOUNT programme gives you a credible, peer-reviewed basis for a conversation, not a guarantee, and not a prescription. A prescriber considering tirzepatide will weigh your BMI, any existing conditions, current medications, and whether the licensed criteria are met. NICE's recommendation in TA1026 covers adults with a BMI of 35 or above alongside at least one weight-related comorbidity, with lower BMI thresholds applying for some ethnic backgrounds under UK guidance.

The trials were conducted alongside reduced-calorie diets and increased physical activity, the licence reflects that. Tirzepatide is not assessed for use without those lifestyle changes in place, as the NHS medicines information for tirzepatide makes clear. Our clinical team reviews every consultation personally, assessing suitability on the full picture rather than BMI alone.

If you have read enough and want a clinical view on whether tirzepatide is appropriate for you, you can speak to our prescribers through a free consultation, reviewed the same day.